Robert Renninger - 30 Jun 2025 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role: SVP, Finance and Accounting
Signature: /s/ Mark Worthington, Attorney-in-Fact on behalf of Robert Renninger
Issuer symbol: ATHA
Transactions as of: 30 Jun 2025
Net transactions value: +$1,462
Form type: 4
Filing time: 02 Jul 2025, 16:32:09 UTC
Previous filing: 12 Mar 2025
Next filing: 29 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Renninger Robert	SVP, Finance and Accounting	C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL	/s/ Mark Worthington, Attorney-in-Fact on behalf of Robert Renninger	02 Jul 2025	0002037968

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ATHA	Common Stock	Award	$2,312	+10,000	+11%	$0.2312	99,724	19 May 2025	Direct	F1, F2, F3
transaction	ATHA	Common Stock	Options Exercise	$0	+12,359	+12%	$0.000000	112,083	30 Jun 2025	Direct
transaction	ATHA	Common Stock	Sale	$850	-2,897	-2.6%	$0.2935	109,186	01 Jul 2025	Direct	F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ATHA	Restricted Stock Units	Options Exercise	$0	-12,359	-50%	$0.000000	12,359	30 Jun 2025	Common Stock	12,359		Direct	F6, F7, F8

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"),for the ESPP Purchase Period (as defined in the ESPP) of November 18, 2024 through May 19, 2025. This transaction is exempt under Rule 16b-3(c).
F2	The Purchase Period ended March 19, 2025 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began November 18, 2024.
F3	In accordance with the ESPP, these shares were purchased based on 85% of the closing price on May 19, 2025.
F4	Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person.
F5	The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $0.2854 to $0.3031, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F6	RSUs convert into common stock on a one-for-one basis.
F7	Each RSU represents a contingent right to receive one (1) share of Issuer's common stock.
F8	On October 1, 2024, the reporting person was granted 37,077 RSUs. One-third (1/3rd) of the RSUs vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates.